Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice

Vaccine

Volumn 23, Issue 44, 2005, Pages 5196-5203

  Yang, Zhi Gang ^a   Sun, Hong Xiang ^a,b   Fang, Wei Huan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Adjuvants; Antibody; Astragalus membranaceus; Haemolysis; OVA; Proliferation; Saponins

Indexed keywords

ACETYLASTRAGALOSIDE I; ADJUVANT; AGROASTRAGALOSIDE III; AGROASTRAGALOSIDE IV; ALUMINUM POTASSIUM SULFATE; ASTRAGALOSIDE I; ASTRAGALOSIDE II; ASTRAGALOSIDE III; ASTRAGALOSIDE IV; ASTRAGALOSIDE V; ASTRAGALOSIDE VI; ASTRAGALOSIDE VII; ASTRAMEMBRANNIN I; ASTRAMEMBRANNIN II; CONCANAVALIN A; CYCLOASTRAGENOL; CYCLOGALEGENIN; HUANGQIYENIN D; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2B; ISOASTRAGALOSIDE I; ISOASTRAGALOSIDE II; LIPOPOLYSACCHARIDE; OVALBUMIN; QUIL A; SAPONIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; ASTRAGALUS MEMBRANACEUS; CELL PROLIFERATION; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG SAFETY; ERYTHROCYTE; HEMOLYSIS; HUMORAL IMMUNITY; IMMUNE RESPONSE; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SPLEEN CELL; STATISTICAL SIGNIFICANCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ASTRAGALUS MEMBRANACEUS; CELL PROLIFERATION; HEMOLYSIS; IMMUNITY, CELLULAR; MICE; OVALBUMIN; SAPONINS;

EID: 25144454868     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.06.016     Document Type: Article

References (75)

1. D.T. O'Hagan, M.L. Mackichan, and M. Singh Recent developments in adjuvants for vaccines against infectious diseases Biomol Eng 18 3 2001 69 85
2. J. Aucouturier, L. Dupuis, and V. Ganne Adjuvants designed for veterinary and human vaccines Vaccine 19 17-19 2001 2666 2672
3. J.C. Cox, and A.R. Coulter Adjuvants - a classification and review of their modes of action Vaccine 15 3 1997 248 256
4. R.T. Coughlin, D. Fish, T.N. Mather, J. Ma, C. Pavia, and P. Bulger Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp)A, OspB, and the saponin adjuvant QS21 J Infect Dis 171 1995 1049 1052
5. L.A. Jackson, and J.P. Opdebeeck The effect of various adjuvants on the humoral response of sheep and cattle to soluble and membrane midgut antigens of Boophilus microplus Vet Parasit 58 1995 129 141
6. M.H. Yen, C.C. Lin, and C.M. Yen The immunomodulatory effect of saikosaponin derivatives and the root extract of Bupleurum kaoi in mice Phytother Res 9 1995 351 358
7. M.F. Powell, J.L. Cleland, D.J. Eastman, A. Lim, K. Murthy, and M.J. Newman Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons AIDS Res Hum Retrovir 10 1994 S105 S108
8. E. Rivera, S. Hu, and C. Concha Ginseng and aluminium hydroxide act synergistically as vaccine adjuvants Vaccine 21 2003 1149 1157
9. E. Rivera, A. Daggfeldt, and S. Hu Ginseng extract in aluminium hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae Vet Immunol Immunopathol 91 2003 19 27
10. S. Hu, C. Concha, F. Lin, and K.P. Waller Adjuvant effect of ginseng extracts on the immune responses to immunisation against Staphylococcus aureus in dairy cattle Vet Immunol Immunopathol 91 2003 29 37
11. G.P. Borja-Cabrera, A. Cruz Mendes, E. Paraguai de Souza, L.Y. Hashimoto Okada, F.A. de ATrivellato, and J.K. Kawasaki Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine Vaccine 22 2004 2234 2243
12. R. Bomford, M. Stapleton, S. Winsor, A. McNight, and T. Andronova The control of the antibody isotype response to recombinant immunodeficiency virus gp120 antigen by adjuvants AIDS Res Hum Retroviruses 8 1992 1765 1771
13. J.Y. Wu, B.H. Gardner, C.I. Murphy, J.R. Seals, C.R. Kensil, and J. Recchia Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine J Immunol 148 1992 1519 1525
14. M.J. Newman, Y.Y. Wu, B.H. Gardner, C.A. Anderson, C.R. Kensil, and J. Recchia Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations Vaccine 15 9 1997 1001 1007
15. W. Britt, J. Fay, and C. Kensil Formulation of an immunogenic human cytomegalovirus vaccine: response in mice J Infect Dis 171 1995 18 25
16. I.A. Khan, K.H. Ely, and L.H. Kasper A purified parasite antigen (p30) mediates CD8+ T cell immunity against fatal Toxoplasm gondii infection in mice J Immunol 147 1991 3501 3506
17. H. Takahashi, T. Takeshita, B. Morein, S. Putney, R.N. Germain, and J.A. Berzofsky Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope proteins in ISCOMS Nature 344 1990 873 875
18. S. Soltysik, J.Y. Wu, J. Recchia, and D.A. Wheeler Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function Vaccine 13 15 1995 1403 1410
19. R.K. Gupta Aluminum compounds as vaccine adjuvants Adv Drug Deliv Rev 32 3 1998 155 172
20. T.P.M. Schetters, J. Kleuskens, N. Choltes, and H.J. Bos Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture Parasite Immunol 14 1992 295 305
21. S.J. Cox, P.V. Barnett, P. Dani, and J.S. Salt Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission Vaccine 17 1999 1858 1868
22. R. Bomford Saponin and other haemolysis (vitamin A, aliphatic amines, polyene antibiotics) as adjuvants for SRBC in the mouse. Evdence for a role of cholesterol-binding in saponin adjuvanticity Int Arch Allergy Appl Immunol 63 1980 170 177
23. C.R. Kensil, J.Y. Wu, and S. Soltysik Structural and immunological characterization of the vaccine adjuvant QS-21 Pharm Biotechnol 6 1995 525 541
24. D.C. Waite, E.W. Jacobson, F.A. Ennis, R. Edelman, B. White, and R. Kammer Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21 Vaccine 19 2001 3957 3967
25. J.L. Cleland, C.R. Kensil, A. Lim, N.E. Jacobsen, L. Basa, and M. Spellman Isomerization and formulation stability of the vaccine adjuvant QS-21 J Pharm Sci 85 1996 22 28
26. D.J. Marciani, J.B. Press, R.C. Reynolds, A.K. Pathak, V. Pathak, and L.E. Gundy Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity Vaccine 18 27 2000 3141 3151
27. D.J. Marciani, A.K. Pathak, R.C. Reynolds, L. Seitz, and R.D. May Altered immunomodulating and toxicological properties of degraded Quillajia saponaria Molina saponins Int Immunopharm 1 2001 813 818
28. G. Liu, C. Anderson, H. Scaltreto, J. Barbon, and C.R. Kensil QS-21 structure/function studies: effect of acylation on adjuvant activity Vaccine 20 2002 2808 2815
29. C.R. Kensil, U. Patel, M. Lennick, and D.J. Marciani Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex J Immunol 146 1991 431 437
30. K. Oda, H. Matsuda, T. Murakami, S. Katajama, T. Oghitani, and M. Yoshikawa Adjuvant and hemolytic activities of 47 saponins derived from medicinal and food plants Biol Chem 381 2000 67 74
31. W.R. Santos, V.M. de Lima, E.P. de Souza, R.R. Bernardo, M. Palatnik, and C.B. Palatnik de Sousa Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis Vaccine 21 2002 30 43
32. H. Chang, and P. But Pharmacology and Applications of Chinese Materia Medica 1987 World Scientific Singapore pp. 1041-1046
33. X.Q. Ma, Q. Shi, J.A. Duan, T.T. Dong, and K.W. Tsim Chemical analysis of Radix Astragali (Huangqi) in China: a comparison with its adulterants and seasonal variations J Agric Food Chem 50 17 2002 4861 4866
34. B.M. Shao, W. Xu, H. Dai, P. Yu, Z. Li, and X.M. Gao A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb Biochem Biophys Res Commun 320 4 2004 1103 1111
35. X. Yin, Y. Zhang, H. Wu, X. Zhu, X. Zheng, and S. Jiang Protective effects of Astragalus saponin I on early stage of diabetic nephropathy in rats J Pharmacol Sci 95 2 2004 256 266
36. L. Verotta, M. Guerrini, N.A. El-Sebakhy, A.M. Asaad, S.M. Toaima, and M.E. Abou-Sheer Cycloartane saponins from Astragalus peregrinus as modulators of lymphocyte proliferation Fitoterapia 72 8 2001 894 905
37. P. Gariboldi, F. Pelizzoni, M. Tato, L. Verotta, N. El-Sebakhy, and A.M. Asaad Cycloartane triterpene glycosides from Astragalus trigonus Phytochemistry 40 6 1995 1755 1760
38. Y. Luo, Z. Qin, Z. Hong, X. Zhang, D. Ding, and J.H. Fu Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia Neurosci Lett 363 3 2004 218 223
39. Y.P. Wang, X.Y. Li, C.Q. Song, and Z.B. Hu Effect of astragaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice Acta Pharmacol Sin 23 2002 263 266
40. E. Bedir, N. Pugh, I. Calis, D.S. Pasco, and I.A. Khan Immunostimulatory effects of cycloartane-type triterpene glycosides from Astragalus species Biol Pharm Bull 23 2000 834 837
41. R. Cui, J.C. He, B. Wang, F. Zhang, G.Y. Chen, and S. Yin Suppressive effect of Astragalus membranaceus Bunge on chemical hepatocarcinogenesis in rats Cancer Chemother Pharmacol 51 2003 75 80
42. J.L. Rios, and P.G. Waterman A review of the pharmacology and toxicology of Asrtagalus Phytother Res 11 1997 411 418
43. M. Takechi, and Y. Tanaka Haemolytic time course differences between steroid and triterpenoid saponins Planta Med 61 1995 76 77
44. W.R. Santos, R.R. Bernardo, Pecanha LMT, M. Palatnik, J.P. Parente, and C.B. Palatnik de Sousa Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani Vaccine 15 9 1997 1024 1029
45. H.X. Sun, YP. Ye, H.J. Pan, and Y.J. Pan Adjuvant effect of Panax notoginseng saponins on the immune responses to ovalbumin in mice Vaccine 22 2004 3882 3889
46. H.X. Sun, Y.P. Ye, and Yuanjiang Pan Immunological adjuvant saponins from the roots of Panax notoginseng Chem Biodiversity 2 4 2005 510 515
47. X.B. Jia, Y. Chen, B.C. Cai, Y.F. Shi, and X.L. Wang Study on the method of purifying astragaloside Chin Tradit Patent Med 25 2003 866 868
48. 3H-thymidin incorporation assay Vet Immunol Immunophathol 70 1999 151 159
49. E.G. Espinet Nuevo tipo de vacuna antiaftosa a complejo glucovirico Gac Vet 74 1951 1 13
50. C.R. Kensil, and R. Kammer QS-21: a water-soluble triterpene glycoside adjuvant Exp Opin Invest Drugs 7 1998 1475 1482
51. P.O. Livingston, S. Adluri, F. Helling, T.J. Yao, C.R. Kensil, and M.J. Newman Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma Vaccine 12 1994 1275 1280
52. F. Helling, S. Zhang, A. Shang, S. Adluri, M. Calves, and R. Koganty GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21 Cancer Res 55 1995 2783 2788
53. M. McCaffery, T.J. Yao, L. Williams, P.O. Livingston, A.N. Houghton, and P.B. Chapman Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside; enhanced immunogenicity when combined with adjuvant Clin Cancer Res 2 1996 679 686
54. K.A. Foon, G. Sen, L. Hutchins, O.L. Kashala, M. Banerjee, and M. Chakraborty Antibody responses in melanoma patients immunized an anti-idiotype antibody mimicking disialoganglioside GD2 Clin Cancer Res 4 1998 1117 1124
55. + T-cell frequencies by the elispot assay in health individuals and in patients with metastatic melanoma immunized with tyrosinase peptide Int J Cancer 87 3 2000 391 398
56. M.C. Keefer, M. Wolff, G.J. Gorse, B.S. Graham, L. Corey, and M.L. Clements-Mann Safety profile of Phase I and II preventive HIV type 1envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group AIDS Res Hum Retroviruses 13 14 1997 1163 1177
57. T.G. Evans, M.J. McElrath, T. Matthews, D. Montefiori, K. Weinhold, and M. Wolff QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans Vaccine 19 2001 2080 2091
58. J.A. Stoute, M. Slaoui, D.G. Heppner, P. Momin, K.E. Kester, and P. Desmons A preliminary evaluation of a recombinant circumsporozoite vaccine against plasmodium falciparum malaria N Engl J Med 336 2 1997 86 91
59. D.C. Van setten, and G. Van de Werken Molecular structures of Quillja saponaria Molina Adv Exp Med Biol 404 1996 185 193
60. L.I. Nord, and L. Kenne Separation and structural analysis of saponins in a bark extract from Quillja saponaria Molina Carbohydr Res 320 1999 70 81
61. C.R. Kensil, J.Y. Wu, C.A. Anderson, D.A. Wheeler, and J. Amsden QS-21 and QS-7: purified saponin adjuvants Dev Bio Stand 92 1998 41 47
62. R. Higuchi, Y. Tokimitsu, T. Fujioka, T. Komori, T. Kawasaki, and D.G. Oakenful Structure of desacylsaponins obtained from the bark of Quillaja saponaria Phytochemistry 26 1987 229 235
63. R. Higuchi, Y. Tokimitsu, and T. Komori An acylated triterpenoid saponin from Quillaja saponaria Phytochemistry 27 1988 1165 1168
64. R. Higuchi, and T. Komori Structure of compounds derived from the acyl moieties of quillajasaponin Phytochemistry 26 1987 2357 2360
65. J.L. Cleland, C.R. Kensil, A. Lim, N.E. Jacobsen, L. Basa, and M. Spellman Isomerization and formulation stability of the vaccine adjuvant QS-21 J Pharm Sci 85 1996 22 28
66. 13C NMR spectroscopy Carbohydr Res 280 1 1996 1 14
67. I. Kitagawa, H.K. Wang, M. Saito, A. Takagi, and M. Yoshikawa Saponin and sapogenol, XXXIV. Chemical constituents of Astragali radix, the root of Astragalus membranaceus bunge. (1). Cycloastragenol, the 9,19-cyclolanostane- type aglycone astragalosides, and the artifact aglycone astrgenol Chem Pharm Bull 31 1983 689 697
68. I. Kitagawa, H.K. Wang, M. Saito, A. Takagi, and M. Yoshikawa Saponin and sapogenol, XXXV. Chemical constituents of Astragali radix, the root of Astragalus membranaceus bunge. (2). Astragalosides, I, II, IV, acetylastragaloside I and isoastragalosides I and II Chem Pharm Bull 31 1983 698 708
69. I. Kitagawa, H.K. Wang, M. Saito, and M. Yoshikawa Saponin and sapogenol XXXVI. Chemical constituents of Astragali radix, the root of Astragalus membranaceus bunge. (3). Astragalosides III, V, and VI Chem Pharm Bull 31 1983 709 715
70. Z. He, and J. Findlay Constituents of Astragalus membranaceus J Nat Prod 54 1991 810 815
71. I. Kitagawa, H.K. Wang, and M. Yoshikawa Saponin and sapogenol XXXVII. Chemical constituents of Astragali radix, the root of Astragalus membranaceus bunge. (4). Astragalosides VII and VIII Chem Pharm Bull 31 1983 716 722
72. D. Wang, W. Shen, Y. Tian, Z. Sun, C. Jiang, and S. Yuan Protective effect of active components extracted from Radix Astragali on human erythrocyte membrane damages caused by reactive oxygen species China J Chin Mater Med 21 1996 746 768
73. Z. Zheng, J. Dai, and M. Zhu Effect of injection of Astragalus membranaceus on the deformability of red blood cells Biorheology 32 1995 322
74. E. Baumann, G. Stoya, A. Völkner, W. Richter, C. Lemke, and W. Linss Hemolysis of human erythrocytes with saponin affects the membrane structure Acta Histochem 102 2000 21 35
75. D. Bensky, and A. Gamble Chinese Herbal Medicine: Materia Medica Revised Edition 1993 Eastland Press Seattle, WA p. 34